Adverse effects of long-term therapeutic doses of quinidine in asymptomatic Brugada patients: should low doses be used first?

Pharmacological therapy is controversial in Brugada syndrome (BrS), but quinidine, an old anti-arrhythmic drug initially proposed by Belhassen and coworkers in this indication, is gaining support from different groups. Bouzeman et al .1 nicely present in this Journal a large series of asymptomatic subjects with BrS who received hydroquinidine and had an electrophysiology study on treatment. The study confirms the low rate of ventricular arrhythmias (VAs) …